Lupin Pharmaceuticals aims to be among the first generic drugmakers to launch GLP-1 receptor agonists, drugs used for treating Type II diabetes and obesity, as part of its broader strategy for market expansion.
The company revealed plans to enter this lucrative market with a focus on products such as semaglutide, the popular weight-loss drug sold globally as Ozempic by Novo Nordisk.
With the patent protection for this category expected to expire in certain markets by 2026, Lupin is positioning itself to capitalize on this opportunity.
Launch Plans
Lupin introduce GLP-1 products to introduce in 2026, with a clear strategy for India and other emerging markets, according to Managing Director Nilesh Gupta.
The company’s approach will involve a combination of in-house development and licensing partnerships to bring the drugs to market efficiently.
Lupin introduce GLP-1 for the internal capabilities to both develop and manufacture these drugs will enable them to enter the segment competitively. Gupta emphasized that a detailed strategy would unfold next year, setting the stage for their market entry.
Target Regions
Lupin is focusing on several regions where the GLP-1 products will become available following patent expiry.
These regions include India, South Africa, Latin America, the Philippines, and parts of Eastern Europe.
CEO Vinita Gupta highlighted these areas as strategic for launching generic GLP-1 products. Lupin’s goal is to capture market share in these high-growth areas as demand for diabetes and obesity treatments continues to rise.
Market Competition
Lupin is not alone in its pursuit of the GLP-1 market. Other Indian pharmaceutical giants such as Cipla, Dr. Reddy’s Laboratories, Wockhardt, and Mankind Pharma are also eyeing the segment.
These companies are looking to develop their own generics for diabetes, obesity, and weight-loss treatments as more GLP-1 drugs lose patent protection.
Novo Nordisk’s injectable version of semaglutide, widely endorsed by celebrities for its weight-loss benefits, has created significant demand, leading to supply pressures.
As reported by thehindubusinessline.com, Cipla’s Managing Director Umang Vohra expressed interest in the category, signalling the company’s intent to partner with Eli Lilly, the maker of Mounjaro (tirzepatide), another weight-loss drug.
